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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not probiotics
are safe and effective in reducing the incidence of diarrhea in HIV-positive individuals.
Study Design: Systematic review of three English language primary studies, published in 1998,
2007, and 2008.
Data Sources: Three double-blind, randomized, controlled trials published after 1996, comparing
administration of probiotics with placebo, were obtained using EBSCOhost, PubMed, and
Cochrane databases.
Outcomes Measured: Frequency and consistency of stools. Daily or weekly questionnaires
allowed subjects to report perceived severity of symptoms using scales containing descriptive
words and figures with corresponding numeric values. Subjects were evaluated initially at
baseline and subsequently at the completion of the studies, and the results were compared.
Results: No intervention-related negative side effects or adverse events were reported in any of
the studies. Anukam and colleagues found that those women treated with probiotics had rapid
resolution of diarrhea compared to controls, for both the duration of treatment at day fifteen and
at follow-up on day ninety. Trois, et al. reports a decrease in loose stools and an increase in
normal stools in both groups but no statistically significant decrease in diarrhea in the probiotic
group as compared with control.
Conclusion: All three studies showed that probiotics are safe when used in children and adults
with HIV/AIDS. Simple comparison of the studies performed by Trois, et al. and Anukam, et al.
suggests that probiotic supplements are more efficacious in adult populations than pediatric
populations in reducing frequency of loose stools. However, the use of anti-retroviral drugs,
geographic location, probiotic bacterial strain, and the cause of diarrhea in these populations may
have impacted the outcomes. More studies containing larger patient sample sizes and including
those in various other countries should be performed to further determine the efficacy of
probiotics in reducing diarrhea and appreciate other health benefits in diverse populations of
HIV-positive individuals.
Key words: probiotics, safety, diarrhea, gastrointestinal, children, adults, HIV, AIDS
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INTRODUCTION
Diarrhea, in both acute and chronic forms, is one of the most common symptoms
experienced by men, women, and children who have been infected with the human
immunodeficiency virus (HIV).1 In its earliest days, HIV/AIDS was described as the “slim
disease” due to advanced wasting and persistent diarrhea, which is still a reality in Africa and
other disadvantaged parts of the world. Diarrhea also contributes as a major cause of morbidity
and mortality for HIV-positive children across the globe.2 Chronic diarrhea is often defined as
three or more loose or liquid stools per day for more than four weeks and/or a daily stool weight
greater than 200 g/day. While acute diarrhea is associated with more pain, blood stream
invasion, and death for HIV patients, both acute and chronic forms of diarrhea threaten overall
health and quality of life.1
Despite increased research efforts and education aimed at eradicating HIV-transmission,
2.6 million new infections are reported worldwide yearly, with 50,000 of these occurring in the
United States.3 The care of HIV-positive individuals in the US is of great cost; for example,
Farquhar, et al. estimated $18.2 billion in HIV-associated economic losses in 2001 alone.4 One
study in Birmingham, Alabama cites costs between $13,885 and $36,532 per HIV patients per
year.5 The chief expenses are generated by medication costs (71-84%) and care for those with
more advanced disease.
Physician Assistants (PAs) are often the sole care provider for HIV-patients. As of 2005,
PAs and Nurse Practitioners (NPs) provided most of the care for 20% of CARE Act Title III HIV
clinics. PAs and NPs performed similarly to those physicians trained in infectious disease and
superiorly to generalist non-HIV experts in 6 of 8 quality measures.6 Therefore, PAs play an
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important role in the management of HIV in the US and particularly in maintaining quality and
specificity of care for these patients.
HIV-related diarrhea is multi-factorial in nature. Infectious and non-infectious causes
prevail, yet all physiological aspects are not fully understood. While they are found in the
serum, the majority of CD4+ T-lymphocytes reside in the mucosal surfaces, particularly the gut.
The intestinal mucosa acts a main target for HIV as well as a “reservoir” for viral replication,
especially in early disease, leading to immune dysregulation through increased apoptosis of
CD4+ lymphocytes.1 Bacterial overgrowth, opportunistic infection, and malabsorption of
nutrients can also result. Numerous infectious agents are often isolated in stool cultures,
including bacterial species (E. coli, Salmonella, Shigella, C. difficile, Mycobacterium,
Campylobacter), viruses (Rotavirus, adenovirus, Cytomegalovirus), protozoan parasites (Giardia
lamblia, Entamoeba histolytica, Cryptosporidium parvum,), and fungi (Candida,
Histoplasmosis).1
Even in the absence of infection, the HIV virus itself causes “profound changes” in the
intestinal mucosa.1 Increased permeability allows for translocation of microbial products across
the gut, which may stimulate innate immune receptors. Villous atrophy and crypt hyperplasia of
the jejunum are common findings, termed, “HIV enteropathy.” Decreased absorption of sugars,
vitamin B12, and other nutrients are linked with chronic diarrhea in HIV patients. Malabsorption
is known to directly affect the CD4 count in HIV children adversely.2 The virus is also
associated with inflammatory bowel disease, pancreatic disease (impaired fat absorption), and
lymphomas including Hodgkin and Non-Hodgkin B-cell, diffuse large B-cell, primary effusion
lymphoma, Burkitt and Burkitt-like lymphomas, and Kaposi sarcoma, all of which have the
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potential for gastrointestinal (GI) symptoms.1 Additionally, diarrhea is one of the most common
side effects of most antiretroviral therapies (ARTs).7
No specific treatment or drug has been approved for HIV-related diarrhea. The main
goals of treatment are to eradicate pathogenic causes, reduce the number of loose stools per day,
manage dehydration, decrease abdominal discomfort, and improve quality of life.7 Antibiotics,
anti-virals, and anti-fungals should be given based on the sensitivity of suspected or isolated
pathogens. While ARTs have helped to decrease chronic diarrhea in Western populations,
practitioners have commonly prescribed antimotility agents, such as loperamide, diphenoxylate,
and codeine, or adsorbents like bismuthsabsalicylate, kaolin/pectin, and attapulgite to control
symptoms. Cholestyramine (for malabsorption of bile salts) and thalidomide (for HIV-related
colitis) have also been employed. Supplementation with vitamin A and zinc have been shown to
reduce gut permeability.1
Probiotics are defined by the Food and Agricultural Organization (FAO) as “live microorganisms which when administered in adequate amounts confer a health benefit on the host”8.
Supplementation has been shown to enhance mucosal immune defense by supporting
macrophages, killer cells, T cells and interferon, and acting against pathogenic colonization and
translocation.2 Their use has been well documented in the alleviation of diarrhea (Lactobacillus
sp) and other unwanted GI symptoms. Probiotics, L. reuteri in particular, have been beneficial in
prophylaxis against cryptosporidiosis, a common pathogen in the HIV population.8 The probiotic
organisms do not remain for extended periods of time in the GI tract, so sufficient quantities
(>1x107/day) are necessary to maintain colonization and immune stimulation.2
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OBJECTIVE
The objective of this selective EBM review is to determine whether or not probiotics are
safe and effective in reducing the incidence of diarrhea in HIV-positive individuals.
METHODS
A number of criteria were considered in selection of studies. The population was limited
to HIV-positive individuals two years old or greater who experience diarrhea. Only double blind
or double-masked, randomized, controlled trials that introduced probiotic supplementation as
compared with visually-matched placebo were considered. The following strains were deemed
acceptable probiotics: Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium
bifidum, and Lactobacillus reuteri. Outcomes of interest included tolerance, adverse events, and
consistency and frequency of stools.
A detailed search was performed by the author of this review between January 2011 and
February 2011 using the Cochrane Library EBM Online Database and PubMed Online, with the
key words “HIV,” “diarrhea,” and “probiotics.” All three articles that were selected to be
included in this review were written in the English language and published in peer-reviewed
journals between 1996 and present. Selection of studies, which was also performed by the
author, was based on relevance to the topic of interest, and only studies that reported patientoriented outcomes (Patient Oriented Evidence that Matters, or POEMs) were accepted. Inclusion
criteria simply included HIV-positive status. Exclusion criteria included individuals with other
chronic diseases, known food or drug allergies, pregnancy, recent (<1 month) changes in ART or
changes during the study. The studies either reported p-values or contained dichotomous data,
which could be used to calculate Relative Risk Reduction/Increase (RRR/RRI), Absolute Risk
Reduction/Increase (ARR/ARI), and Numbers Needed to Treat/Harm (NNT/NNH).
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Demographics of the three final selections are reported and displayed in Table 1.
Table 1. Demographics and characteristics of included studies
Study
Type
# of
Age
Inclusion
Exclusion
patients
Criteria
Criteria
Anukam,
Double24
18-44
HIV (+)
Lactose
20089
blind,
females age intolerance,
RCT
18-44,
currently
CD4>200
taking
cells/mcL
supplements
or ARTs

Trois,
20082

Doubleblind,
RCT

77

2-12

Wolf,
199810

Doubleblind,
RCT

39

18-65

HIV (+)
children
who
acquired
the disease
perinatally,
one child
who
acquired by
blood
products
HIV(+)
males and
nonpregnant
females (at
least 6
weeks postpartum);
CD4 count
>400

W/D

Intervention

2

100mL
conventional
yogurt/day
fermented with
Lactobacillus
delbruekii subsp.
Bulgaris and
Streptococcus
thermophilus
supplemented
with L.
rhamnosus GR-1
and L. reuteri
RC-14 at 107/mL
14g/day of a
standard formula
containing
Bifidobacterium
bifidum and
Streptococcus
thermophilus at
2.5 x 1010 CFU
diluted in 100 mL
of milk

Chronic
diseases or
allergies;
Changes in
ART in past
3 months or
during the
study

1

Known drug
or food
allergy;
Individuals
taking any
ART other
than
Zidovudine

4

1010 CFU
Lactobacillus
reuteri (strain
SD2112)/day in a
beverage <37°C
[ex: tap water,
milk, orange juice
from concentrate,
apple juice, grape
juice, cranberry
juice, 7-up]
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OUTCOMES
All three studies ascertained POEMs by gathering reports from participants. Wolf, et al.
were concerned mainly with safety and tolerance of probiotics. A review of systems was taken
at baseline for comparison of the efficacy of implemented therapy. By completing daily
questionnaires, subjects reported the severity of diarrhea using the following scale: 0 = absent,
1= mild, 2 = moderate, and 3 = severe; subjects also reported the number of bowel movements
daily and the consistency using the following scale: 1 = hard, dry; 2 = hard, formed; 3 = soft,
formed; 4 = soft, unformed; 5 = watery.10 Trois, et al. also used previously approved reference
questionnaires, which were completed by the subjects’ parents, to determine the frequency and
consistency of stools in each 24-hour period. Drawings depicting stools varied from watery to
normal and had corresponding numeric scores.2 Anukam, et al. developed a structured
questionnaire given at baseline, fifteen days, thirty days, and three months. Participants rated
diarrhea episodes as absent, moderate (daily episodes of watery stools), or severe (persistent
watery stools, urgency and frequency of defecation).9
RESULTS
Safety. Results of all three studies support the safety of using various probiotics in HIV
patients. Wolfe, et al. found no statistically significant difference (p<0.05) in the frequency and
consistency of stools between the control group and those receiving 1010 colony-forming units
(CFU) of L. reuteri per day during any week of the study. Baseline values were not reported,
and results were presented based on percent of subject days. Using this method, most GI
tolerance factors were absent for the majority (>80%) of study days (See Table 2). No p-values
were reported for these. Both groups reported a greater amount of flatulence, but those receiving
probiotics experienced less. A potential side effect, mild or moderate nausea, was reported by

Horvath	
  7	
  
Probiotics	
  and	
  HIV	
  diarrhea	
  
18.26% of the probiotic group, as compared with only 6.72% of the control group. However,
those taking probiotics reported no significant vomiting or reflux. The experimental group also
reported slightly higher, but not statistically significant, incidence of constipation and distention;
these were still absent 93.31% and 86.08% of the time, respectively. All data was continuous,
rather than dichotomous, and no baseline values were reported for comparison or for further
calculations. Results are reported in Table 3. Anukam, et al. saw no adverse effects in the
probiotic group, including any significant change in key lab values—total WBCs, neutrophils,
lymphocytes, RBCs, hemoglobin, hematocrit, or platelet count (see Table 4)—while three in the
control group experienced rashes during the study. Trois et al. did not report any adverse
reactions in the children studied.
Table 2. GI tolerance factors of L. reuteri reported by Wolfe, et al., 199810
Parameter
Treatment
Absent
Mild
Moderate
Severe
Placebo
62.89*
23.67
12.89
0.56
Flatulence
L. reuteri
67.45
19.53
9.4
3.62
Placebo
93.14
5.46
1.26
0.14
Nausea
L. reuteri
81.56
14.1
4.16
0.18
Placebo
99.58
0.28
0.14
0.0
Vomiting
L. reuteri
97.47
1.99
0.54
0.0
Placebo
95.66
3.78
0.42
0.0
Reflux
L. reuteri
94.21
4.88
0.9
0.14
Placebo
97.06
1.82
1.12
0.0
Constipation
L. reuteri
93.31
3.62
1.27
1.81
Placebo
91.32
3.92
4.62
0.14
Distention
L. reuteri
86.08
7.96
2.71
3.25
*Results reported in percentage of subject-days
Table 3. Safety and Tolerance of L. reuteri reported by Wolfe, et al.,199810
Week 1
Week 2
Week 3
Week 4
Week 5
a
Frequency
NS
NS
NS
NS
NS
b
Consistency NS
NS
NS
NS
NS
a
P-values represent the level of significance for each week comparing placebo with L. reuteri;
NS = not significant (p>0.05).
b
Fecal consistency score: 1 = hard, dry; 2 = hard, formed; 3 = soft, formed; r = soft, unformed; 5
= watery.
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Efficacy. The success of probiotic supplementation in reducing diarrhea varied
significantly between the trials. Anukam, et al. studied adult females living in Nigeria and used
conventional yogurt fermented with Lactobacillus delbruekii subsp. bulgaris and Streptococcus
thermophilus and supplemented with 2.5x109 CFU/day of L. rhamnosus, GR-1 and L. reuteri
RC-14. All participants admitted to moderate diarrhea at baseline. The authors saw a “complete
resolution” of diarrhea in 12/12 women in the experimental group by the second day of the
study, which lasted for the remainder of the treatment period (day 15), as compared with only
one control group participant. At the ninety-day follow-up, 8/12 that received the probiotics still
reported a total absence of diarrhea, while only 2/12 of those in the control group reported its
absence. Risk and treatment statistics are summarized in Table 4.
Table 4. Diarrhea reduction with L. reuteri and L. rhamnosus reported by Anukam, et al., 20089
RBIa
ABIa
NNT a
Adverse Eventsb
c
Day 2 of treatment
100%
1 subject
NR, NSd
Day 15 (full duration of treatment)
10.1
91%
2 subjects
NR, NS
Day 90 (post-treatment follow-up)
2.99
50%
3 subjects
NR, NS
a
RBI = Relative benefit increase; ABI = Absolute benefit increase; NNT = Numbers needed to
treat
b
Adverse events in those receiving probiotics; NR = none reported;
C
Could not be calculated
d
NS = not significant; pertaining to p-values (all >0.05) comparing laboratory values at baseline
and day 30 for the following hematologic parameters: TWBC, neotrophils, lymphocytes, RBCs,
HB, HCT, MCV, MCH, MCHC, RDW, and platelets
Trois, et al. did not see the same overwhelming efficacy with the children studied in
Brazil. Those in the experimental group received 2.5x1010 CFU of Bifidobacterium bifidum and
Streptococcus thermophilus. Both groups experienced a statistically significant (p<0.05)
decrease in number of liquid stools and an increase number of in normal stools. Notably, no
statistical difference existed between the groups. Results of this study are presented in Table 5.
Children under age 2 or greater than 12 years were excluded from participating in this study.
Only one subject in the probiotics group did not adhere to the treatment regimen yet was still
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included in the results due to his or her intention to be treated. One subject in the control group
became hospitalized and was removed entirely from the study. Overall, the adults who received
L. rhamnosus and L. reuteri experienced greater resolution of diarrhea than did the children who
received B. bifidum and S. thermophilus.
Table 5. Changes in stool with B. bifidum and S. thermophilus reported by Trois, et al., 20072
Outcome measured
p from
Significance
p between
Significanceb
baselinea
groups
Decrease in # if liquid stools
0.006 Significant
0.522
NSc
Decrease in # of loose-soft stools
0.955
NS
Not reported
Increase in # of normal stools
0.001 Significant
0.199
NS
a
p-values from baseline were reported to be statistically the same in both placebo and group
receiving Bifidobacterium bifidum and Streptococcus thermophilus when compared with
respective baseline values.
b
Statistical significance of p-value comparison between treatment groups
c
NS = Not significant; a p-value is deemed significant if <0.05.
DISCUSSION
The author was unable to find another systematic review written to date concerning the
use of probiotics to alleviate HIV-related diarrhea. The study performed by Wolfe, et al. was the
pioneer trial to test and prove the safety of probiotics in HIV-positive patients. The study by
Anukam, et al. showed great reduction of diarrhea but may be limited by a sample size of only
twelve subjects in each group, experimental and control, who were not using any ART. The
subjects in Trois, et al. were using ART, which is notorious for producing the adverse effect of
diarrhea. This difference could contribute to the discrepancy in results. Anukam, et al. only
provided fifteen days of treatment, while Trois provided 60 days. It has been noted that the
effects of probiotics differ and are unique to each strain.8 The women in Nigeria were given L.
rhamnosus and L. reuteri, while the children in Brazil were given B. bifidum and S.
thermophilus. These differences could also be contributing to such varied results. The nature of
the diarrhea in each subject was not ascertained before beginning the studies, so the exact
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mechanisms by which the probiotics were functioning in alleviating or not alleviating diarrhea
could not be determined for certain.
Supplementation with probiotics continues to be an area of intense research for HIV and
many other conditions. Multiple studies have shown that probiotics also effectively increase the
CD4 count in people with HIV/AIDS.9,11 Strong evidence exists to support benefits against acute
diarrhea from rotavirus and in preventing surgical complications like pouchitis. Other areas that
have been explored are prevention of necrotizing enterocolitis (NEC), traveler’s diarrhea, H.
pylori infection, the control of irritable bowel syndrome (IBS), inflammatory bowel disease
(IBD), reducing the risk of bladder and colon cancer, vulvovaginal candidiasis and other
urogenital problems, respiratory infections, atopic conditions, and dental caries.8,12
The most common side effects noted across studies have been flatulence and bloating,
which are not considered dangerous and are usually mild.8 Wolfe, et al. noted both of these to be
present in subjects of that study.10 While they have never been proven in a clinical trial, the most
serious potential adverse events are bacteremia and fungemia, which have been documented in
the past as isolated cases. These are extremely rare, estimated 1 in 1 million and 1 users in 1.69
million users, respectively; yet the severely immunocompromised are considered among those at
highest risk.8 Probiotic use has also been associated with increased mortality in patients with
severe acute pancreatitis. Lactobacillus preparations are contraindicated for those with a
hypersensitivity to lactose or milk, and S. boulardii for patients with yeast allergies. Currently,
no contraindications for Bifidobacteria exist. Probiotics are available as supplements (i.e.,
tablets, capsules, or powders) or as fermented dairy products (i.e., yogurt and milk) and have not
yet been evaluated by the FDA for the creation of specific recommendations or regulations.8
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CONCLUSION
The articles reviewed demonstrate that probiotic supplementation is safe in HIV patients,
but the evidence is conflicting regarding its efficacy in reducing the incidence of diarrhea in this
population. No adverse events were attributed to probiotic use. The evidence provided by
Aunkam, et al. is promising and is reason enough to pursue the intervention further. The Food
and Agriculture Organization (FAO) and World Health Organization (WHO) published a 2001
Report on Probiotics that recommended “efforts be made to take probiotics to developing
countries.”13 Motivated by the work of Anukam, et al., a group called Western Heads East
(WHE) has created a community kitchen in Mwanza, Tanzania for producing a probiotic yogurt
named Fiti, which uses L. rhamnosus GR-1. Trials have been completed but not yet published,
which showed fewer episodes of diarrhea in HIV-positive individuals who received Fiti yogurt
(p<0.01 in one trial and p=0.05 in another).13 Future trial designs should include control groups
of adults who are using ART to determine the benefits to this segment of the HIV population, as
ART is becoming more available. Because probiotics are relatively inexpensive, widely
available, and generally safe, trials such as these should continue, especially in children and
adults of impoverished areas around the globe, in order to aid these individuals and to expand
what is known about the various benefits of probiotic supplementation.
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